Literature DB >> 17009064

[Cocaine abuse in Vienna and European cities--a multi-center study].

Andjela Bäwert1, Nicole Primus, Reinhold Jagsch, Harald Eder, Margarete Zanki, Kenneth Thau, Gabriele Fischer.   

Abstract

INTRODUCTION: As cocaine consumption seems to have increased over the last decades, the EU has funded this multi-center, cross-sectional survey to investigate cocaine consumption in three different target groups. The study was conducted by the Addiction Clinic, Department of Psychiatry, Medical University Vienna and other nine European cities.
METHODS: Data were collected by structured face-to-face interviews. The sample was composed of 211 cocaine abusers out of three target groups: (1) treatment group undergoing opioid maintenance therapy, (2) marginalized scene group and (3) integrated party group. Sociodemographic data such as age, education, employment, monthly expenses on cocaine/crack, data on consumption patterns, physical and mental health and personal needs regarding cocaine consumption were evaluated. Urine toxicology results for cocaine in the treatment group completed the analysis.
RESULTS: The marginalized scene group was the oldest with a mean age of 29.35 years, with the highest unemployment rate (mean 25.11 days) and the longest duration of cocaine consumption (mean 5.80 years). They had the highest cocaine consumption pattern with a mean of 22.32 days within the last month. On average 1969 Euros/months was spent for their addiction. The treatment group had the lowest school education with a mean of 10.36 years, but showed a sufficient insight in their cocaine problem. However, the party group (with the lowest mean age, 25.64 years) highly underestimated their drug problem, the mean amount of money they spent for their addiction was 588.99 Euro/months. Structured urine toxicology between 1996 and 2002 in patients undergoing opioid maintenance therapy ("treatment group") revealed a significant increase of concomitant cocaine consumption (1996: 33.1%; 2002: 40.2%; p = 0.044). DISCUSSION: The European trend of increased cocaine use could also be observed in Vienna. One of the greatest barriers for establishing adequate treatment settings for this target group is the difficulty to reach this population. In addition, multiple substance abuse seems to be one of the predominating patterns of cocaine consumption and this aspect should be integrated within treatment (in the treatment and scene groups additional heroin and benzodiapzepines abuse is observed, in the party group intensive alcohol consumption). The Viennese results are in line with those of the other European cities; however, it could not be confirmed that consumption of crack cocaine and binge play a similarly significant role as in cities such as Hamburg or London.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17009064     DOI: 10.1007/s00508-006-0661-7

Source DB:  PubMed          Journal:  Wien Klin Wochenschr        ISSN: 0043-5325            Impact factor:   1.704


  29 in total

1.  Cardiovascular complications of cocaine use.

Authors:  R A Lange; L D Hillis
Journal:  N Engl J Med       Date:  2001-08-02       Impact factor: 91.245

2.  Routes of drug administration and multiple drug misuse: regional variations among clients seeking treatment at programmes throughout England.

Authors:  M Gossop; J Marsden; D Stewart; S Treacy
Journal:  Addiction       Date:  2000-08       Impact factor: 6.526

3.  Severity of dependence and route of administration of heroin, cocaine and amphetamines.

Authors:  M Gossop; P Griffiths; B Powis; J Strang
Journal:  Br J Addict       Date:  1992-11

4.  Prevalence and correlates of crack-cocaine injection among young injection drug users in the United States, 1997-1999.

Authors:  Scott S Santibanez; Richard S Garfein; Andrea Swartzendruber; Peter R Kerndt; Edward Morse; Danielle Ompad; Steffanie Strathdee; Ian T Williams; Samuel R Friedman; Lawrence J Ouellet
Journal:  Drug Alcohol Depend       Date:  2005-03-07       Impact factor: 4.492

Review 5.  Recent advances in the psychotherapy of addictive disorders.

Authors:  Kathleen M Carroll
Journal:  Curr Psychiatry Rep       Date:  2005-10       Impact factor: 5.285

Review 6.  Follow-up of infants prenatally exposed to cocaine.

Authors:  Cassandra Schiller; Pat Jackson Allen
Journal:  Pediatr Nurs       Date:  2005 Sep-Oct

Review 7.  Cardiovascular complications of cocaine.

Authors:  A H Mouhaffel; E C Madu; W A Satmary; T D Fraker
Journal:  Chest       Date:  1995-05       Impact factor: 9.410

8.  Pathobiological determinants of cocaine-associated cardiovascular syndromes.

Authors:  F D Kolodgie; A Farb; R Virmani
Journal:  Hum Pathol       Date:  1995-06       Impact factor: 3.466

Review 9.  Pharmacological treatments for heroin and cocaine addiction.

Authors:  Wim van den Brink; Jan M van Ree
Journal:  Eur Neuropsychopharmacol       Date:  2003-12       Impact factor: 4.600

10.  Efficacy of disulfiram and cognitive behavior therapy in cocaine-dependent outpatients: a randomized placebo-controlled trial.

Authors:  Kathleen M Carroll; Lisa R Fenton; Samuel A Ball; Charla Nich; Tami L Frankforter; Julia Shi; Bruce J Rounsaville
Journal:  Arch Gen Psychiatry       Date:  2004-03
View more
  3 in total

1.  Influence of site differences between urban and rural American and Central European opioid-dependent pregnant women and neonatal outcome characteristics.

Authors:  Andjela Baewert; Reinhold Jagsch; Bernadette Winklbaur; Gerda Kaiser; Kenneth Thau; Annemarie Unger; Constantin Aschauer; Manfred Weninger; Verena Metz
Journal:  Eur Addict Res       Date:  2012-02-21       Impact factor: 3.015

2.  [Cocaine addiction: the therapeutic challenge by diversified addiction pattern].

Authors:  Christian Haasen; Katja Thane
Journal:  Wien Klin Wochenschr       Date:  2006-09       Impact factor: 1.704

3.  Eosinophilic pneumonia associated with heroin inhalation: a case report.

Authors:  Apostolos Tsapas; Konstantinos Paletas; Efthymia Vlachaki; Eleni Bekiari; Constantine Spanos; Dimitrios Economidis
Journal:  Wien Klin Wochenschr       Date:  2008       Impact factor: 1.704

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.